ABEONA THERAPEUTICS INC. Debt Securities, Available-for-sale, Amortized Cost
ABEONA THERAPEUTICS INC. (ABEO) had Debt Securities, Available-for-sale, Amortized Cost of $90.68 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-13
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $90.68M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $106.92M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $112.83M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $124.22M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost | Debt Securities, Available-for-sale, Amortized Cost as first filed |
|---|---|---|
| 2026-06-30 | $90.68M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $106.92M 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $112.83M 10-Q · filed 2026-08-13 | |
| 2025-09-30 | $124.22M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $62.03M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $68.28M 10-Q · filed 2025-05-15 | |
| 2024-12-31 | $74.36M 10-K · filed 2026-03-17 | |
| 2024-09-30 | $94.06M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $88.42M 10-Q · filed 2024-08-12 | |
| 2024-03-31 | $44.97M 10-Q · filed 2024-05-15 | |
| 2023-12-31 | $37.82M 10-K · filed 2025-03-20 | |
| 2023-09-30 | $49.14M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $30.61M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $35.72M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $38.03M 10-K · filed 2024-03-18 | |
| 2022-09-30 | $12.45M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $13.97M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $10.99M 10-Q · filed 2022-05-13 | |
| 2021-12-31 | $12.08M 10-K · filed 2023-03-29 | $12.09M 10-K · filed 2022-03-31 |
| 2021-09-30 | $23.22M 10-Q · filed 2021-11-15 | |
| 2021-06-30 | $50.38M 10-Q · filed 2021-07-28 | |
| 2021-03-31 | $72.50M 10-Q · filed 2021-05-17 | |
| 2020-12-31 | $82.45M 10-K · filed 2022-03-31 | |
| 2020-09-30 | $88.43M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $93.20M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $75.50M 10-Q · filed 2020-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |